Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Q1FY2020
Business Updates
2
Disclaimer
This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of anyoffer to buy or subscribe for, any securities in Cordlife Group Limited (“Cordlife”) in Singapore or any other jurisdictionnor shall it or any part of it form the basis of, or be relied on in connection with, any investment decision, contract orcommitment whatsoever in this or any jurisdiction. This presentation may contain forward-looking statements thatinvolve assumptions, risks and uncertainties. Actual future performance, outcomes and results may differ materiallyfrom those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions.You are cautioned not to place undue reliance on these forward-looking statements, if any, which are based on thecurrent view of management on future events. The information contained in this presentation has not beenindependently verified. No representation or warranty expressed or implied is made as to, and no reliance should beplaced on, the fairness, accuracy, completeness or correctness of the information or opinions contained in thispresentation. Neither Cordlife or any of its affiliates, advisers or representatives shall have any liability whatsoever (innegligence or otherwise) for any loss howsoever arising, whether directly or indirectly, from any use, reliance ordistribution of this presentation or its contents or otherwise arising in connection with this presentation. The pastperformance of Cordlife is not indicative future performance. The value of shares in Cordlife (“Shares”) and theincome derived from them may fall as well as rise. Shares are not obligations of, deposits in, or guaranteed by,Cordlife or any of its affiliates. An investment in Shares is subject to investment risks, including the possible loss of theprincipal amount invested.
3
Content
Overview1
Financial Highlights
Growth Strategies
2
3
4
Outlook
4
Overview
Business Overview – Operating Segments
⚫ Collection at birth, processing,
testing, cryopreservation and storage
of stem cells from the umbilical cord
blood – Haematopoietic Stem
Cells (HSCs)
Cord Blood Banking
⚫ Collection, processing, testing,
cryopreservation and storage of the
umbilical cord lining - Mesenchymal
stem cells (MSCs) and Epithelial stem
cells (EpSCs)
⚫ Patented technology – Exclusive license
from CRC.
Cord Lining Banking
⚫ A non-invasive, early detection test specially
designed to screen inherited metabolic
disorders in newborns.
Non-invasive Newborn Metabolic Screening
Banking Diagnostics
⚫ Non-invasive detection of vision problems in
children
⚫ Catered for children as early as 6 months to 6
years old
⚫ Instant results provided to enable early
intervention
Paediatric Vision Screening
Cord Tissue (Wharton’s Jelly) Banking
⚫ A whole-exome genetic test that cross-
analyses genetic information within the family
to let them take steps to delay, manage or
even prevent the onset of the condition/s that
they are predisposed to
Family Genetic Testing
⚫ Collection, processing, testing,
cryopreservation and storage of the
umbilical cord tissue - Mesenchymal
stem cells (MSCs)
3
⚫ Catered for expectant women in their 1st
trimester
⚫ Analyses cell free foetal DNA in mother’s blood
to detect foetal chromosomal abnormalities
using whole genome sequencing
Non-Invasive Prenatal Testing (NIPT)
Singapore Hong Kong India Philippines Indonesia Malaysia
1. Cordlife Cordlife Lifecell Cordlife Cordlife Cryocord
2. StemCord Cryolife CryoBanks Stemcord Babybanks Cordlife
3. Cryoviva Prostemcell Cordlife Globetek Stemcord Cellsafe
Total # of
Companies4 6 12 4 6 3
India
Myanmar
Thailand
Vietnam
Malaysia
Singapore
Indonesia
Hong Kong
Philippines
Banking Services
Diagnostics Services
Cordlife’s Headquarters
Cordlife’s Subsidiaries
Cordlife’s Associate
Cordlife’s Marketing Agents
Our ReachBusiness Overview – Market Presence
4
Bangladesh
7
Financial Highlights
8
1QFY2020 Results Summary
REVENUE
S$14.5 million(0.5%) y-o-y
GROSS PROFIT
S$9.1 million0.5% y-o-y
GP MARGIN
63.2%0.6 pp y-o-y
NET PROFIT
S$1.5 million+69.9% y-o-y
NET PROFIT MARGIN
10.3%+4.2 pp y-o-y
NET CASH1
S$58.0 million+S$8.3 million from 31 Dec 19
1: Includes cash and cash equivalents, fixed deposits and short-term investments less interest-bearing borrowings (current and non-current)
9
Analysis of 1QFY2020
Revenue
Net Profit
Net profit after tax grew 69.9% yoy to S$1.5 million, mainly driven by
(a) higher gross profit
(b) lower administrative expenses
(c) lower marketing expenses (attributable to lower advertising and promotion expenses due to the outbreak
of COVID-19).
Despite the worsening of the COVID-19 situation, the Group maintained its revenue at S$14.5 million with higher
revenue contribution from diagnostics services as well as the Indonesia and Philippines markets.
S$ mil
10
Financials – Revenue
%
49.1
57.6 59.6
51.5
61.4 61.6
14.6 14.5
0
10
20
30
40
50
60
70
80
FY2014* FY2015* FY2016* FY2017# 12M2018# FY2019# 1Q2019 1Q2020
* Prepared in accordance with FRS18 – Revenue. # Prepared in accordance with SFRS(I) 15 – Revenue from Contracts with Customers.
S$ mil
11
Financials – Gross Profit
%
34.9 40.0 39.5
30.3
38.3 39.7
9.1 9.1
71.069.4
66.3
58.9
62.564.5
62.6 63.2
0.11.63.14.66.17.69.110.612.113.615.116.618.119.621.122.624.125.627.128.630.131.633.134.636.137.639.140.642.143.645.146.648.149.651.152.654.155.657.158.660.161.663.164.666.167.669.170.672.173.6
0
10
20
30
40
50
60
70
80
90
FY2014* FY2015* FY2016# FY2017# 12M2018# FY2019# 1Q2019 1Q2020
Gross Profit Gross Profit Margin
* Prepared in accordance with FRS18 – Revenue. # Prepared in accordance with SFRS(I) 15 – Revenue from Contracts with Customers.
%%
%
%
%%
%
%
12
Financials – Operating profit after tax
S$ mil
7.6
5.0
2.2
0.5
1.2
5.8
0.9
1.5
15.5
8.7
3.71.0 2.0
9.46.1
10.3
-60.0
-45.0
-30.0
-15.0
0.0
15.0
0
1
2
3
4
5
6
7
8
9
10
FY2014* FY2015* FY2016* FY2017# 12M2018# FY2019# 1Q2019 1Q2020
Net Profit Net Profit Margin
* Prepared in accordance with FRS18 – Revenue. # Prepared in accordance with SFRS(I) 15 – Revenue from Contracts with Customers.
%%
%%%
%
%
%
13
Financials – Balance Sheet
S$’ mil As at 31 Mar 2020 As at 31 Dec 2019
Net Assets 131.0 129.3
Borrowings 4.2 4.3
Gearing1 (%) 3.2 3.3
Cash & Cash Equivalents, Fixed
Deposits and Short-term Investments62.2 53.8
Net Asset Value Per Share (SG cents) 51.56 50.89
1: Total Borrowings/Total Equity
14
S$’ mil As at 31 Mar 2020 As at 31 Mar 2019
Net cash generated from operating activities 3.5 2.7
Net cash generated from/(used) in investing
activities2.7 (1.5)
Net cash used in financing activities (0.08) (0.08)
Cash & cash equivalents at end of the
financial period21.7 12.3
Financials – Cash Flow
15
Outlook
16
Outlook
Impact of COVID-19
➢ Ramp up online counseling and e-enrollment of clients.
➢ Convert face to face seminar/antenatal class to webinars.
➢ Social distancing measures have restricted many marketing events which may impact signups.
17
Growth Strategies
18
Growth Strategies
• To increase penetration rate/market share
• To increase market depth
• To facilitate development of stem cell ecosystem
• To create new engines of growth
M&A
Organic Growth
• Synergistic with current business
• Earnings accretive
• Targeting Asia
19
Thank you